register

News & Trends - MedTech & Diagnostics

Patients lose out in private health insurers’ race to the bottom

Health Industry Hub | November 7, 2019 |

The continual spread of misinformation by the private health insurance industry around the causes of higher than expected private health insurance premium increases is a race to the bottom that will ultimately leave Australian patients worse off.

“It is incumbent on all players in the industry to work collaboratively to ensure the sustainability of our healthcare system moving forward,” said Ian Burgess, MTAA CEO, today.

“Access to modern life-saving technology through the Prostheses List is a key part of the value proposition of private health insurance.

“Sustained attempts by the insurers to restrict and water down patient access to medical technology is now presenting a very real risk of further diminishing the value of the product they sell.

“The devices industry was the sole contributor to lower private health insurance premium increases both in 2017 and in 2018. MTAA’s Agreement with the Government is on track to exceed $1.1 billion in expected savings.

“Patients deserve better than to be caught in the middle of a race to the bottom being inflicted on them by a private health insurance industry that has failed to address its own issues.

The recently released AlphaBeta report, Keeping Premiums Low: Towards a more sustainable private healthcare system, found that insurers have collected 50% more profit from each of their members over the past five years, far outpacing the 21% growth in benefits paid out.

It also found that private health funds have not extracted sufficient economies of scale in the wake of significant revenue growth and many funds are well above the industry average of 9% in operational expenditure, this includes an estimated marketing spend of $400 million.

Medical devices make up less than 10 per cent of private insurance benefits.

“Medibank profits are up 25% from the start of 2019, yet affordability for ordinary Australian families is going down,” Mr Burgess said.

“Patient and clinician choice is a key part of the value proposition of private health insurance, one that risks being eroded by the false claims made by insurers about the cost of devices.

“The medical technology industry believes access to a full range of medical technology is one of the key benefits of having private health insurance and we’re committed to helping ensure all Australians lead healthier and more productive lives,” Mr Burgess concluded.

You may also like Insurers fail to address sustainability issues, blame everyone else for it

Register FREE to access Health Industry Hub’s e-news bulletin; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and key stakeholders.


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.